Expression and clinical significance of WWOX and PTEN protein in bronchogenic carcinoma

doi:10.3877/cma.j.issn.1674-6902.2017.06.016

Abstract

Abstract:

Objective

To investigate the expression of WW domain containing oxidoreductase (WWOX) and phosphatase and tension homology deleted on chromosome ten(PTEN) in bronchogenic carcinoma and their clinical significance, as well as their relationship.

Methods

It was detected that the expression of WWOX and PTEN in lung tissues from 87 patients with bronchogenic carcinoma and 23 healthy lung tissues by immunohistochemical analysis.

Results

The positive expression rates of both WWOX and PTEN were lower in cancer tissues than in normal lung tissues (χ²=14.810, P=0.000; χ²=17.363, P<0.001). Also, the expression of WWOX was related with gender, differentiation, clinical stages, lymph node metastasis (P<0.05), not related with age and the tumor size (P>0.05); the expression of PTEN was only related with lymph node metastasis (P<0.05), but not related with other clinical significance (χ²=2.098, P<0.001). There was no significant relationship between the expression of WWOX and PTEN.

Conclusions

Both WWOX and PTEN proteins may be able to influence the occurrence and development of bronchogenic carcinoma, but it is more likely that they function through different pathways.

Key words: WW domain containing oxidoreductase, Phosphatase and tension homology deleted on chromosome ten, Bronchogenic carcinoma, Correlativity analysis

Jin Zhang, Zhouhuan Dong, Ming Zhao, Zhiqiang Xue, Yuqi Wang, Xiaodong Tian, Yunxi Wang. Expression and clinical significance of WWOX and PTEN protein in bronchogenic carcinoma[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(06): 709-712.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.06.016

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I06/709

Figures/Tables 3

References 24

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1):1-6.
2	Strassen U, Hofauer B, Matsuba Y, et al. Bronchogenic cancer: It still exists[J]. Laryngoscope, 2016, 126(3):638-642.
3	Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth[J]. Cancer Res, 2001, 61(22):8068-8073.
4	Mahajan NP, Whang YE, Mohler JL, et al. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox[J]. Cancer Res, 2005, 65(22):10514-10523.
5	Chang NS, Pratt N, Heath J, et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity[J]. J Biol Chem, 2001, 276(5):3361-3370.
6	Kremer EJ, Pritchard M, Lynch M, et al. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n[J]. Science, 1991, 252(5013):1711-1714.
7	Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis[J]. Nature, 2005, 436(7051):725-730.
8	Heavey S, O′Byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC[J]. Cancer Treat Rev, 2014, 40(3):445-456.
9	Printz C. Lung cancer new leading cause of death for women in developed countries: Data reflects increased rates of smoking[J]. Cancer, 2015, 121(12):1911-1912.
10	Schrock MS, Huebner K. WWOX: a fragile tumor suppressor[J]. Exp Biol Med (Maywood), 2015, 240(3):296-304.
11	Puciennik E, Nowakowska M, Stpien A, et al. Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer[J]. Oncol Lett, 2014, 8(5):2291-2297.
12	Huang YC, Hung WC, Chen WT, et al. Expression of WWOX and FHIT is downregulated by exposure to arsenite in human uroepithelial cells[J]. Toxicol Lett, 2013, 220(2):118-125.
13	Del MS, Husanie H, Iancu O, et al. WWOX and p53 dysregulation synergize to drive the development of osteosarcoma[J]. Cancer Res, 2016, 76(20):6107-6117.
14	Nowakowska M, Puciennik E, Wujcicka WI, et al. The correlation analysis of WWOX expression and cancer related genes in neuroblastoma-a real time RT-PCR study[J]. Acta Biochim Pol, 2014, 61(1):91-97.
15	Nowakowska M, Pospiech K, Lewandowska U, et al. Diverse effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines[J]. Tumour Biol, 2014, 35(9):9291-9301.
16	Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma[J]. Cancer, 2004, 100(8):1605-1614.
17	Lin JT, Li HY, Chang NS, et al. WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase[J]. Cell Cycle, 2015, 14(3):408-416.
18	Li G, Sun L, Mu Z, et al. Ectopic WWOX expression inhibits growth of 5 637 bladder cancer cell in vitro and in vivo[J]. Cell Biochem Biophys, 2015, 73(2):417-425.
19	Ekizoglu S, Bulut P, Karaman E, et al. Epigenetic and genetic alterations affect the WWOX gene in head and neck squamous cell carcinoma[J]. PLoS One, 2015, 10(1):e0115353.
20	Dahia PL. PTEN, a unique tumor suppressor gene[J]. Endocr Relat Cancer, 2000, 7(2):115-129.
21	Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications[J]. Curr Cancer Drug Targets, 2008, 8(3):187-198.
22	Sushma PS, Jamil K, Kumar PU, et al. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population[J]. Tumour Biol, 2016, 37(6):7625-7632.
23	Xiao WZ, Han DH, Wang F, et al. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis[J]. Tumour Biol, 2014, 35(7):6687-6693.
24	Zhang X, Park JS, Park KH, et al. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer[J]. Oncology, 2015, 88(2):76-85.

组别	组织类型	例数	表达强度				阳性率(%)
组别	组织类型	例数	－	＋	＋＋	＋＋＋	阳性率(%)
WWOX蛋白	肺癌组织	87	61(70.1)	25(1.1)	1(0.0)	0	29.9
?	正常肺组织	23	6(26.1)	5(21.7)	8(34.8)	4(17.4)	73.9
PTEN蛋白	肺癌组织	87	50(57.5)	26(29.9)	11(12.6)	0(0.0)	42.5
?	正常肺组织	23	2(8.7)	1(4.3)	3(13.0)	17(73.9)	91.3

组别	组织类型	例数	表达强度				阳性率(%)
组别	组织类型	例数	－	＋	＋＋	＋＋＋	阳性率(%)
WWOX蛋白	肺癌组织	87	61(70.1)	25(1.1)	1(0.0)	0	29.9
?	正常肺组织	23	6(26.1)	5(21.7)	8(34.8)	4(17.4)	73.9
PTEN蛋白	肺癌组织	87	50(57.5)	26(29.9)	11(12.6)	0(0.0)	42.5
?	正常肺组织	23	2(8.7)	1(4.3)	3(13.0)	17(73.9)	91.3

临床资料		例数	WWOX		χ²值	P值	PTEN		χ²值	P值
临床资料		例数	－	＋	χ²值	P值	－	＋	χ²值	P值
年龄(岁)		?	?	?	2.481	0.115	?	?	0.478	0.489
?	<60	48	37	11	?	?	26	22	?	?
?	≥60	39	24	15	?	?	24	15	?	?
性别		?	?	?	5.686	0.017	?	?	3.305	0.069
?	男	65	50	15	?	?	41	24	?	?
?	女	22	11	11	?	?	9	13	?	?
肿瘤大小(cm)		?	?	?	5.987	0.014	?	?	1.584	0.208
?	≤4	30	26	4	?	?	20	10	?	?
?	>4	57	35	22	?	?	30	27	?	?
组织分化程度		?	?	?	11.987	0.001	?	?	1.382	0.239
?	中低	65	52	13	?	?	35	30	?	?
?	高	22	9	13	?	?	15	7	?	?
临床分期		?	?	?	0.066	0.796	?	?	3.312	0.069
?	Ⅰ～Ⅱ	52	37	15	?	?	34	18	?	?
?	Ⅲ	35	24	11	?	?	16	19	?	?
淋巴结转移		?	?	?	4.806	0.028	?	?	10.942	0.001
?	无	48	29	19	?	?	20	28	?	?
?	有	39	32	7	?	?	30	9	?	?

临床资料		例数	WWOX		χ²值	P值	PTEN		χ²值	P值
临床资料		例数	－	＋	χ²值	P值	－	＋	χ²值	P值
年龄(岁)		?	?	?	2.481	0.115	?	?	0.478	0.489
?	<60	48	37	11	?	?	26	22	?	?
?	≥60	39	24	15	?	?	24	15	?	?
性别		?	?	?	5.686	0.017	?	?	3.305	0.069
?	男	65	50	15	?	?	41	24	?	?
?	女	22	11	11	?	?	9	13	?	?
肿瘤大小(cm)		?	?	?	5.987	0.014	?	?	1.584	0.208
?	≤4	30	26	4	?	?	20	10	?	?
?	>4	57	35	22	?	?	30	27	?	?
组织分化程度		?	?	?	11.987	0.001	?	?	1.382	0.239
?	中低	65	52	13	?	?	35	30	?	?
?	高	22	9	13	?	?	15	7	?	?
临床分期		?	?	?	0.066	0.796	?	?	3.312	0.069
?	Ⅰ～Ⅱ	52	37	15	?	?	34	18	?	?
?	Ⅲ	35	24	11	?	?	16	19	?	?
淋巴结转移		?	?	?	4.806	0.028	?	?	10.942	0.001
?	无	48	29	19	?	?	20	28	?	?
?	有	39	32	7	?	?	30	9	?	?

WWOX	PTEN		χ²值	P值
WWOX	－	＋	χ²值	P值
－	32	29	2.098	0.147
＋	18	8	2.098	0.147

Please choose a citation manager

Content to export